Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 June 2008, Vol. 111, No. 12, pp. 5418.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Mahieux, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mahieux, R.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

InsideBlood

IMMUNOBIOLOGY

Comment on Grant et al, page 5601

HTLV-I, Tax: fox hunting still allowed

Renaud Mahieux

INSTITUT PASTEUR, INSERM

A defect in TGF-β signaling is observed in HTLV-I–infected cells obtained from HAM/TSP patients. This is associated with low levels of Foxp3 expression and with disruption of both T regulatory and T effectors functions. Disruption of TGF-β signaling is therefore likely to participate in HAM/TSP pathogenesis.

HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP) develops in a subset of human T lymphotropic virus type I (HTLV-I)–infected individuals.1 Its evolution is chronic and progressive, without remission.2 Recently, a study using a histone deacetylase inhibitor reported, for the first time, a spectacular decline in the HTLV-I proviral load in a series of HAM/TSP patients.3 Unfortunately, clinical benefits were limited.

Although it is known that Tax proviral load and a dysregulated immune response play major roles in disease progression, HAM/TSP pathogenesis is still poorly understood. To explain the role of HTLV-I in the progression of HAM/TSP, 3 mechanisms have been proposed1: an antiviral attack mediated by cytotoxic T lymphocytes,2 an autoimmune response,3 or bystander damage due to cytokines such as TNF-{alpha}.4

CD4+/CD25+ T cells expressing the forkhead transcription factor Foxp3 are defined as regulatory T cells (Tregs). These cells play a key role in the maintenance of immune system homeostasis. As shown by 2 recent reports, Tregs from HAM/TSP patients express low levels of Foxp3 and have impaired suppressor functions,5,6 while another apparently conflicting set of findings shows a strong negative correlation between the frequency of circulating CD4+ Foxp3+ Tax Tregs and the rate of cytotoxic T lymphocyte–mediated lysis of autologous HTLV-I–infected cells.7 Prior to the findings reported by Grant and colleagues in this issue of Blood, the mechanism leading to defective Treg function was not clear.

Because TGF-β signaling is involved in Foxp3 expression and Treg suppressor function, Grant and colleagues investigated whether TGF-β signaling was affected in CD4+ cells isolated from HAM/TSP patients. They first demonstrated that the levels of TGF-β receptor II (TGF-βRII) were low in these cells, and that an inverse correlation between TGF-βRII expression and Tax proviral load could be measured. Interestingly, the capability of TGF-β to induce Foxp3 expression in CD+/CD25 Foxp3 cells isolated from HAM/TSP patients was also weakened. Then, they showed that knocking out the expression of Smad4, a TGF-inducible gene, caused a massive reduction in Foxp3 levels, confirming that integrity of the TGF-β signaling pathway must be maintained for normal Foxp3 expression. However, whether the Foxp3 promoter contains Smad4 binding sites or not, and how exactly TGF-β signaling is impaired by HTLV-I, remains to be determined. Is the mechanism similar to that previously described for HTLV-I adult T-cell leukemia/lymphoma cells?8

Finally, the authors established that CD4+/CD25+ T cells isolated from a series of HAM/TSP patients failed to suppress the proliferation of CD4+/CD25 T cells isolated from the same individuals. This latter population was also resistant to suppression mediated by Treg cells obtained from normal donors.

Altogether, these results undoubtedly show that because of a defect in TGF-β signaling, Foxp3 expression is decreased, and both Treg and effector T-cell functions are impaired in HAM/TSP patients. It is tempting to speculate that these deficiencies play key roles in the progression of the disease.

Footnotes

Conflict-of-interest disclosure: The author declares no competing financial interests. {blacksquare}

REFERENCES

  1. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. 1985;2:407–410.[CrossRef][Medline] [Order article via Infotrieve]

  2. Taylor GP, Goon P, Furukawa Y, et al. Zidovudine plus lamivudine in human T-lymphotropic virus type-I-associated myelopathy: a randomised trial. Retrovirology. 2006;3:63.[CrossRef][Medline] [Order article via Infotrieve]

  3. Lezin A, Gillet N, Olindo S, et al. Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients. Blood. 2007;110:3722–3728.[Abstract/Free Full Text]

  4. Bangham CR, Osame M. Cellular immune response to HTLV-1. Oncogene. 2005;24:6035–6046.[CrossRef][Medline] [Order article via Infotrieve]

  5. Oh U, Grant C, Griffith C, Fugo K, Takenouchi N, Jacobson S. Reduced Foxp3 protein expression is associated with inflammatory disease during human T lymphotropic virus type 1 infection. J Infect Dis. 2006;193:1557–1566.[CrossRef][Medline] [Order article via Infotrieve]

  6. Yamano Y, Takenouchi N, Li HC, et al. Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-I-associated neuroimmunological disease. J Clin Invest. 2005;115:1361–1368.[CrossRef][Medline] [Order article via Infotrieve]

  7. Toulza F, Heaps A, Tanaka Y, Taylor GP, Bangham CR. High frequency of CD4+FoxP3+ cells in HTLV-1 infection: inverse correlation with HTLV-1-specific CTL response. Blood. 2008;111:5047–5053.[Abstract/Free Full Text]

  8. Arnulf B, Villemain A, Nicot C, et al. Human T-cell lymphotropic virus oncoprotein Tax represses TGF-beta 1 signaling in human T cells via c-Jun activation: a potential mechanism of HTLV-I leukemogenesis. Blood. 2002;100:4129–4138.[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Dysregulation of TGF-β signaling and regulatory and effector T-cell function in virus-induced neuroinflammatory disease
Christian Grant, Unsong Oh, Karen Yao, Yoshihisa Yamano, and Steven Jacobson
Blood 2008 111: 5601-5609. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Mahieux, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mahieux, R.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020